Editorial Comment

    March 2013 in “ Urology ”
    Rachel L. Kyllo, Sam B. Bhayani, Gerald L. Andriole
    TLDR 5-ARI therapy may help prevent prostate cancer progression.
    The study discussed the use of 5-alpha reductase inhibitors (5-ARIs) in men undergoing active surveillance for low-risk prostate cancer (PCa), which had been controversial. It provided evidence suggesting that 5-ARI therapy could be beneficial, aligning with the REDEEM trial findings. Specifically, 75% of men receiving 5-ARI showed no evidence of pathologic cancer progression at the restaging biopsy after a median follow-up of 35 months.
    Discuss this study in the Community →